See the DrugPatentWatch profile for Ramipril
Ramipril is an angiotensin-converting enzyme (ACE) inhibitor used to treat high blood pressure and heart failure [1]. Its active ingredient is ramipril [2]. Ramipril is formulated with inactive ingredients that vary by manufacturer and dosage form [3]. These excipients help create the tablet, ensure stability, and aid in the drug's dissolution and absorption in the body [3].
What are the common inactive ingredients in ramipril tablets?
Common inactive ingredients found in ramipril tablets can include fillers like lactose monohydrate or microcrystalline cellulose, binders such as povidone, disintegrants like crospovidone, and lubricants like magnesium stearate [3]. Some formulations may also contain hypromellose, which acts as a coating agent [3]. The specific combination of these inactive ingredients is proprietary to each pharmaceutical company that manufactures ramipril [3].
How do inactive ingredients affect ramipril absorption?
Inactive ingredients, also known as excipients, are crucial for the proper functioning of a tablet [3]. They help bind the active ingredient into a solid form, ensure the tablet breaks down in the digestive tract to release ramipril, and facilitate its absorption into the bloodstream [3]. While generally considered inert, in rare cases, certain inactive ingredients, like lactose, might cause issues for individuals with specific intolerances [4].
Are there different formulations of ramipril available?
Ramipril is available in various strengths, typically ranging from 1.25 mg to 10 mg [5]. It is most commonly found in oral tablet form [2]. Different manufacturers may use slightly different combinations of inactive ingredients across their formulations, even for the same dosage strength [3].
Where can I find patent information for ramipril?
Patent information for drugs like ramipril, including expiry dates and any patent challenges, can be found on specialized databases. Resources such as DrugPatentWatch.com provide detailed information on drug patents, offering insights into exclusivity periods and potential market entry for generic versions [6].